Newsroom

PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced the presentation of new preclinical data supporting its SEND (Synthetic Efficacy eNableD) T cell armoring strategy at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, taking place May 11–15, 2026, in Boston. The data will be presented in a poster entitled, “SEND – A T cell ar...

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere’s website at https://ir.travere.com/events-and-presentations. Foll...

PHOENIX--(BUSINESS WIRE)--SmartRent today announced the launch of its strategic value-added reseller program to serve small and mid-market multifamily owners and operators....

NEW YORK--(BUSINESS WIRE)--Rithm Capital Corp. (NYSE: RITM) ("Rithm"), a global alternative asset manager, today announced that its commercial real estate platform Paramount Group, has officially rebranded as Elecor Properties ("Elecor"), a premier real estate platform redefining the modern workplace. The new identity reflects a strategic transformation from a high quality, Class A office portfolio into an operating platform built for the next evolution of the workplace. Elecor Properties is pu...

WATERTOWN, Mass.--(BUSINESS WIRE)--Dyno Therapeutics to present new capsids and AI advancements in gene delivery at the 29th American Society of Gene & Cell Therapy Annual Meeting...

BOSTON--(BUSINESS WIRE)--Strand Therapeutics to present preclinical data on its programmable mRNA in vivo CAR-T platform at the ASGCT 2026 Annual Meeting...

LONDON & NEW YORK--(BUSINESS WIRE)--AviadoBio Ltd. (“AviadoBio”) and Apertura Gene Therapy (“Apertura”), a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, today announced a licensing agreement for Apertura’s TfR1 CapX™, a novel, intravenously-delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1), cross the blood-brain barrier, and enable broad distribution to the brain and spinal cord. Under the agreement, AviadoBio will leve...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sail to Present Preclinical Data Supporting Advancement of Its In Vivo eRNA™ CAR-T Product Candidate to the Clinic at ASGCT 2026 and TIDES USA 2026...

OLD GREENWICH, Conn.--(BUSINESS WIRE)--Ellington Financial Inc. (NYSE: EFC) ("we") today announced an estimated book value per share of common stock of $13.56 as of March 31, 2026. This estimate includes the effect of the previously announced monthly dividend of $0.13 per share of common stock, to be paid on April 30, 2026 to holders of record on March 31, 2026, with the same ex-dividend date. Cautionary Statement Regarding Forward-Looking Statements Estimated book value per common share is sub...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mirai Bio to Unveil Two Next Generation Programs for Targeted Nucleic Acid Delivery Beyond the Liver at ASGCT 2026...